Clinical trials: Phase I
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00134004
- Testing
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil
- Where
- 3 sites in United States
- Volunteers
- 210 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Thyroid Neoplasms
Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
This is a Phase 2 study being conducted at multiple centers in the United States. Patients having thyroid cancer that has spread to other parts of the body (i.e., metastatic) are eligible to participate.
- Trial name
- NCT00094055
- Testing
- AG013736
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pfizer
Renal Insufficiency
PF-04634817 Renal Impairment Study
Patients with renal impairment are the target population for PF-04634817. The clearance mechanism of this drug means that exposure may be increased in subjects with renal impairment.
- Trial name
- NCT01791855
- Testing
- PF-04634817
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Neoplasms
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
This is a safety and pharmacokinetics study of favezelimab as monotherapy and in combination with pembrolizumab AND favezelimab/pembrolizumab as monotherapy in adults with metastatic solid tumors for which there is no available…
- Trial name
- NCT02720068
- Testing
- Favezelimab, Pembrolizumab, Oxaliplatin
- Volunteers
- 481 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)
This is a Phase 1, open label, fixed sequence study of the effect of multiple dose PF-06650833 on single dose OC PK in healthy female subjects.
- Trial name
- NCT05064332
- Testing
- PF-06650833, Ethinyl estradiol (EE) and levonogestrel (LN)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Pfizer
Thrombocytopenia
Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets
This study is to evaluate the safety of intravenous (IV) infusion of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP) in participants with World Health Organization (WHO) Grade 2 bleed in spite of receiving a transfusion…
- Trial name
- NCT02078284
- Testing
- CPP, LSP
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- U.S. Army Medical Research and Development Command
Solid Tumors
A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)
This study will investigate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) activity of adavosertib, both as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in participants with…
- Trial name
- NCT00648648
- Testing
- adavosertib, gemcitabine, cisplatin
- Volunteers
- 206 people
- Sponsor
- Merck Sharp & Dohme LLC
Dry Age-related Macular Degeneration, Macular Degeneration
FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD
This was an open label first in human Phase I/II multicentre study of GT005 in subjects with Macular Atrophy due to Age-related macular degeneration (AMD).
- Conditions
- Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Eye Diseases
- Trial name
- NCT03846193
- Testing
- GT005, GT005 / Device: Orbit™ Subretinal Delivery System
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 56 people
- Sponsor
- Gyroscope Therapeutics Limited
AL Amyloidosis
Daratumumab for the Treatment of Patients With AL Amyloidosis
Participants with AL Amyloidosis will receive the drug daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month.
- Trial name
- NCT02841033
- Testing
- daratumumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Boston Medical Center
Renal Insufficiency, Acute, Renal Insufficiency, Chronic
Evaluate Safety and Pharmacokinetics of Minocin (Minocycline) for Injection in Subjects With Renal Insufficiency
This is a Phase 1, open-label, single-dose study of the safety, tolerability, and pharmacokinetics of Minocin® (minocycline) for injection in subjects with renal insufficiency.
- Conditions
- Renal Insufficiency, Acute, Renal Insufficiency, Chronic, Healthy Subjects
- Trial name
- NCT02808052
- Testing
- Minocin (minocycline) for Injection
- Where
- Germany
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Advanced Solid Malignancies, Malignant Lymphoma
Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma
The purpose of this study is to investigate the safety and tolerability of AZD 1208 up to a maximum tolerated dose (MTD) and define the dose(s) for further clinical evaluation when given daily to patients with advanced solid…
- Trial name
- NCT01588548
- Testing
- AZD1208
- Where
- 3 sites in Japan, United Kingdom
- Volunteers
- 43 people
- Sponsor
- AstraZeneca
Friedreich's Ataxia
Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia
The objectives of the study are: To evaluate the safety and tolerability of single and multiple oral doses of VP 20629 in subjects with Friedreich's ataxia (FA).
- Trial name
- NCT01898884
- Testing
- VP 20629
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Shire
Healthy Volunteers
Guanfacine Immediate-release Electrocardiogram Results (QTc) Study
To assess the effect of immediate-release guanfacine hydrochloride, administered at therapeutic and supratherapeutic doses, on QT/QTc in healthy normal males and females
- Trial name
- NCT00672984
- Testing
- immediate release guanfacine hydrochloride, moxifloxacin
- Where
- United States
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Shire
Human Papillomavirus Infection, Stage I Oral Cavity Squamous Cell Carcinoma
Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer
This pilot clinical trial studies how well durvalumab before surgery works in treating patients with oral cavity or oropharynx cancer.
- Conditions
- Human Papillomavirus Infection, Stage I Oral Cavity Squamous Cell Carcinoma, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT02827838
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Wake Forest University Health Sciences
Recurrent Head and Neck Cancer
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
Primary Objective: The primary objective of the study is to evaluate the safety of repeat administration of a dose level of Ad/PNP plus fludarabine phosphate (F-araAMP) which demonstrated anti-tumor activity in patients with…
- Trial name
- NCT03754933
- Testing
- Ad/PNP, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- GeoVax, Inc.
Hemophilia B
A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B
This study will examine the safety and efficacy of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) for the control and prevention of bleeding episodes in subjects who have previously received factor…
- Trial name
- NCT01361126
- Testing
- Recombinant Coagulation Factor IX Albumin Fusion Protein
- Where
- 2 sites in Bulgaria, Israel
- Volunteers
- 17 people
- Sponsor
- CSL Behring
Lymphangioleiomyomatosis
Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
Specific Aim 1: To investigate whether, in Lymphangioleiomyomatosis (LAM) patients, the combination of sirolimus and hydroxychloroquine is safe and well tolerated Specific Aim 2: To investigate whether, in LAM patients, 6 months…
- Trial name
- SAIL (NCT01687179)
- Testing
- "Sirolimus" and "Hydroxychloroquine" 200 mg, "Sirolimus" and "Hydroxychloroquine" 400 mg
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Brigham and Women's Hospital
Breast Cancer
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00408408
- Testing
- bevacizumab, capecitabine, cyclophosphamide
- Where
- 442 sites in United States, Canada and 1 more
- Volunteers
- 1,206 people
- Sponsor
- NSABP Foundation Inc
Advanced Solid Tumors
First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)
The purpose of this study was to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), maximum tolerated dose (MTD) (if reached) and early signs of efficacy of M4076 monotherapy in participants with…
- Trial name
- NCT04882917
- Testing
- M4076
- Where
- 3 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Eosinophilic Esophagitis
Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation
This is a Phase 1, investigator- and participant-blinded, placebo-controlled, randomized, crossover study to compare bioavailability of AQ280 following single oral doses of a capsule formulation versus a tablet for oral…
- Trial name
- NCT07093008
- Testing
- AQ280 Capsule, AQ280 Tablet for Oral Suspension
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- AQILION AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.